The deal is priced on trailing earnings. The value depends on what comes next.
A quality-of-earnings review verifies the trailing twelve months. It can't prove what comes next. Historical EBITDA and future earnings are different propositions, and the value depends on whether the earnings, cash and growth in the plan are actually attainable.
I investigate which assumptions behind a deal's value are supported, which remain unproven, and what operating changes would make the value attainable. I work with acquirers, private equity firms, portfolio companies and owners, before the deal and after it.
Author of Exit Bomb and Sell Company Up to 10X · As seen in The Wall Street Journal, Bloomberg Television and SUCCESS
Assess
Which assumptions behind the value are supported, which remain unproven, and what could stop the value from arriving. You receive a written assessment with findings and recommendations.
- When
- Before you buy, sell or combine
Prepare
Make the earnings provable before a buyer tests them: transfer the founder's decision criteria, put operating evidence on record, and show that capacity converts.
- When
- Before a sale or a recap
Integrate
Test the integration and synergy plan against customer promises, and design the decision rights acquired units need to act as one company. Your team leads execution.
- When
- After the close
Every number can be verified while nothing explains how.
Deal teams check what happened. Bankers test the price, quality-of-earnings firms test the numbers, and lawyers test the rights. Each does its job. None is engaged to test whether the operating decisions behind those numbers will survive the transfer.
| What diligence verifies | What stays unproven |
|---|---|
| Revenue, contracts and customers | Why the margin happened, and whether a successor can repeat it |
| EBITDA and its adjustments | Pricing and scheduling judgment that was never written down |
| Org chart and management team | Decisions that still route back to the founder |
| Systems, assets and capacity on paper | Whether that capacity can actually be used to deliver |
| The synergy plan | What the synergies remove that customers were paying for |
The gap between a verified result and a reproducible one is where value is lost after the deal.
How capacity becomes enterprise value, and where it breaks
Capacity isn't the only source of value in a deal. It's the one diligence leaves unexamined. Every company converts what it pays for into what it's worth through the same six links. Quality-of-earnings work starts at the last two links. Value is created or lost across all six, beginning with the first.
-
01Paid capacityWhat you fund: people, plants, systems.Breaks whenCapacity is counted but never tested.
-
02Usable capacityWhat can actually be put to work on real customer work.Breaks whenOpen hours can't do the job, stock can't be promised, or authority to act is missing.
-
03Delivered outputWhat reaches the customer.Breaks whenA faster step feeds a slower one and the gain becomes a queue.
-
04Operating profitThe earnings the buyer is paying for.Breaks whenMargin depends on judgment held by one person or a retired team.
-
05CashWhat the earnings actually release.Breaks whenWorking capital and reinvestment needs stay out of sight.
-
06Enterprise valueWhat a buyer can underwrite.Breaks whenDependence raises risk, or growth is claimed on capacity that doesn't convert.
A valuation rests on three questions about capacity
I don't put a multiple on drag. I show which part of the value rests on capacity that hasn't been proven, and what it would take to prove it.
An independent assessment of which assumptions behind a deal's value are supported, and which are not
For an acquisition, a sale, a recapitalization or an integration. What I examine:
- The strategic thesis. What the transaction is expected to make possible, and what that expectation depends on.
- The synergy case. Which synergies are real, which are optimistic, and what each one depends on.
- The earnings base. What drives it, and what it depends on.
- The operating reality. Whether the company can deliver the plan the price assumes.
- The integration path. What to protect, what to combine, and who decides across units.
What you receive: a written assessment with findings and recommendations: what is proven, what isn't, what to protect, what to fix, and what to test before relying on it.
How it differs from an Executive Intervention: an Executive Intervention examines the structural drag inside one company. The M&A Assessment is tied to a transaction. It tests the investment thesis, the synergy case and the integration path, on the deal's timeline, and it can cover the target, the acquirer and the combination.
The assessment does not replace valuation, quality-of-earnings or legal work. It tests the operating assumptions those depend on.
For private equity: the capacity behind the value-creation plan
Every value-creation plan assumes capacity: that the team can absorb growth, the founder's judgment will transfer, add-ons will work together, and cost programs won't cut what customers pay for. Those assumptions may never be tested on real work before the plan depends on them.
Across the hold, I work with deal teams, operating partners and portfolio-company CEOs at the points where capacity decides value.
| Point in the hold | The capacity question | Read first |
|---|---|---|
| At entry | Which earnings drivers have evidence behind them, and which rest on people or inference? | Field Case 09 |
| The first 100 days | Which assumptions in the value-creation plan depend on capacity nobody has tested? | S01 · S02 |
| Founder recap and leadership change | Are decision criteria transferring, or only titles? | Field Case 10 |
| Add-ons and roll-ups | Who can decide across the acquired units when one unit's numbers get worse? | Field Case 11 |
| Cost and synergy programs | What does the cut remove that customers were paying for? | Field Case 12 |
| Technology and AI investments | Is the gain reaching the customer, or piling up in a queue? | Field Case 13 · S06 |
| Before exit | Will the next buyer's diligence find earnings it can reproduce? | S03 |
For operating partners: a focused, evidence-led look at the capacity behind the plan, delivered as a written findings report, without placing a team inside the company for months.
Where I fit, whoever owns the company
Would your earnings survive if you stepped away?
I examine decisions only you can make, margin that depends on your judgment, and capacity a buyer will count but can't use. Sellers are paid for what they can prove.
Which earnings drivers can this team reproduce from records alone?
Operating evidence alongside the quality-of-earnings review: which drivers have evidence behind them, which rest on inference, and which rest on people who may leave.
Synergy realization that doesn't cut what customers pay for
Cost synergies are easy to book and easy to overshoot. Revenue synergies need the authority to decide across units. I test the synergy plan against customer promises before the cuts land, and give the combined company a rule for choices that cross its businesses.
The thinking behind this, published
- Field Cases 09–12: the ownership seriesFour composite companies after a sale, a recapitalization, a roll-up and an integration.
- S03 · The Deal Closed. Did the Value Transfer?Four ways acquisition value fails to transfer, and when it does transfer.
- Research 05 · Acquisition Without Value ConversionWhat public-company deal disclosures show, and what they can't diagnose.
- The Company Behind the EBITDAReported, reproducible and underwritable are three different things.
- The Structural Drag Diagnostic StandardThe rules every finding has to meet.
The Field Cases are fictional composites built to teach mechanisms. They aren't client stories or benchmarks.
Where I sit next to your deal team
| Role | What they verify |
|---|---|
| Investment banker | The process, the buyers and the price |
| Quality-of-earnings firm | The numbers |
| Legal counsel | The rights and obligations |
| Gower Idrees | Which assumptions behind the value are supported, and what it will take to make the value attainable |
Bankers, quality-of-earnings providers and operating partners bring me in when the numbers are clean but the bigger question isn't settled: will this deal deliver the value it is priced on?
Three questions worth asking this week
When I lead a sale myself
On rare occasions, I personally lead a sell-side transaction: strategic sales above $100 million where there is real value to realize. I take on very few, by choice.
Before the next acquisition, sale or integration plan
Assess a deal, prepare a company or plan an integration
Start a confidential conversation about an M&A Assessment: which assumptions behind the value are supported, which are not, and what it would take to make the value attainable.
Discuss an M&A AssessmentA single company, a portfolio business or a smaller decision?
Book a 15-Min Drag Check to discuss whether a Focused or Comprehensive Executive Intervention fits. The findings come to you in a written report. Strengthening the company, preserving what works, or changing nothing all remain valid outcomes.
Book a 15-Min Drag CheckGower Idrees · Creator of the Business Structural Drag framework and the Renergy™ management framework · Explore the Methodology
